Y-mAbs Therapeutics, Inc. (CIK: 0001722964) EDGAR, Information, Filings... CompaniesBIO.Com

Y-

Y-mAbs Therapeutics, Inc.

Mailing address
230 PARK AVENUE, SUITE 3350, NEW YORK, Delaware, 10169
Phone
212-847-9841
State location
New York
State of incorporation
Delaware
Fiscal year end
December 31
SIC
2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS
Filings
N/A

Y-mAbs Therapeutics, Inc. (CIK: 0001722964) is an American company incorporated in the state of New York. Head office is located at 230 PARK AVENUE, SUITE 3350, NEW YORK, New York, 10169. Work in the industry 2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS. Y-mAbs Therapeutics, Inc. is a public company and trade via Over-The-Counter (OTC).

Owner	Filings	Transaction Date	Type of Owner
Smith Susan Laura	0001901039	Dec-14-2021	officer: Senior Vice President, CCO
Hamill Laura	0001751804	Jun-11-2020	director
Rajah Vignesh	0001815042	Jun-02-2020	officer: SVP and CMO
Herman Philip Karl	0001799303	Jan-01-2020	officer: Sr. VP and CCO
Ahmed Mahiuddin	0001799304	Jan-01-2020	officer: Sr. VP and CSO
Raskin Gregory S	0001753646	Aug-29-2019	director
Ber Gerard	0001762144	Dec-11-2018	director
GILL DAVID N	0001106519	Sep-20-2018	director
HEALY JAMES	0001245624	Sep-20-2018	director
TYAGI ASHU	0001752467	Sep-20-2018	director
Kruse Bo	0001752940	Sep-20-2018	director, officer: EVP, CFO, Secy & Treas.
Lund-Hansen Torben	0001753134	Sep-20-2018	officer: Sr. VP and Head of Tech Op
Lisby Steen	0001753152	Sep-20-2018	officer: Sr. VP and CMO
Wedell-Wedellsborg Johan	0001753185	Sep-20-2018	director, 10 percent owner
WG Biotech ApS	0001753193	Sep-20-2018	10 percent owner
Juan Moller San Pedro Claus	0001753222	Sep-20-2018	director, officer: Chief Executive Officer
Gad Thomas	0001753224	Sep-20-2018	director, officer: President and Chairman
Wilms Joris	0001753231	Sep-20-2018	officer: Sr. VP and COO
Buschle Michael	0001753357	Sep-20-2018	director

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Y-mAbs Therapeutics, Inc.

Filings	Format	Description	Filed/Effective	File/Film Number
144	Document	Filing for proposed sale of securities under Rule 144 Acc-no: 0001968582-24-000828 (33 Act) Size: 0 KB	Sep-13-2024	001-38650 241298002
144	Document	Filing for proposed sale of securities under Rule 144 Acc-no: 0001964306-24-000334 (33 Act) Size: 0 KB	Sep-03-2024	001-38650 241274858
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001415889-24-022629 ( Act) Size: 0 KB	Aug-30-2024
144	Document	Filing for proposed sale of securities under Rule 144 Acc-no: 0001964306-24-000328 (33 Act) Size: 0 KB	Aug-28-2024	001-38650 241256623
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001415889-24-022326 ( Act) Size: 0 KB	Aug-27-2024
144	Document	Filing for proposed sale of securities under Rule 144 Acc-no: 0001964306-24-000321 (33 Act) Size: 0 KB	Aug-26-2024	001-38650 241241360
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0001558370-24-011795 (34 Act) Size: KB	Aug-12-2024	001-38650 241194712
8-K	Document	Current report filing Acc-no: 0001558370-24-011792 (34 Act) Size: KB	Aug-12-2024	001-38650 241194685
8-K	Document	Current report filing Acc-no: 0001558370-24-009915 (34 Act) Size: KB	Jul-19-2024	001-38650 241127952
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001415889-24-019529 ( Act) Size: 0 KB	Jul-12-2024
3	Document	Initial statement of beneficial ownership of securities Acc-no: 0001415889-24-019393 ( Act) Size: 0 KB	Jul-08-2024
8-K	Document	Current report filing Acc-no: 0001558370-24-009643 (34 Act) Size: KB	Jul-01-2024	001-38650 241090888
8-K	Document	Current report filing Acc-no: 0001558370-24-009614 (34 Act) Size: KB	Jun-28-2024	001-38650 241085956
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001104659-24-071403 ( Act) Size: 0 KB	Jun-13-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001104659-24-071402 ( Act) Size: 0 KB	Jun-13-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001104659-24-071401 ( Act) Size: 0 KB	Jun-13-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001104659-24-071400 ( Act) Size: 0 KB	Jun-13-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001104659-24-071399 ( Act) Size: 0 KB	Jun-13-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001104659-24-071398 ( Act) Size: 0 KB	Jun-13-2024
8-K	Document	Current report filing Acc-no: 0001104659-24-071250 (34 Act) Size: KB	Jun-13-2024	001-38650 241041214

Recent 20 filings. View all Y-mAbs Therapeutics, Inc. filings

Overall rating 5.0

Aug 22, 2022

Pelisari

young lad who new his job ansered questions and new what was best for me.

Aug 22, 2022

Catherine

Thanks I look forward to using the product to improve my skin tone

Aug 22, 2022

Samuel Ejimofor

It's being easier working on the website. And I recommend, it's a great website

Y-mAbs Therapeutics, Inc. overview
Y-mAbs Therapeutics, Inc. job
Y-mAbs Therapeutics, Inc. stock
Y-mAbs Therapeutics, Inc. ownership
Y-mAbs Therapeutics, Inc. CEO
Y-mAbs Therapeutics, Inc. documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.